You are here
Regulatory decisions and announcements
Important decisions and announcements relating to advertisements of therapeutic goods will be published here. This includes certain compliance and enforcement actions, such as direction letters and public warning notices regarding non-compliant ads when required.
- Notices of approved and permitted restricted representations
- Advertising directions notices
- TGA cracking down on non-compliant advertising of bioresonance and similar devices
Conviction for unlawful advertising of sports supplements
30 September 2020 On 29 July 2020, the ACT Magistrates Court convicted the former owner of a Canberra-based sports supplements company on four charges of unlawful advertising of therapeutic goods.
Court proceedings commenced against HEALTHHUB247 and its director for alleged illegal activity relating to performance enhancing drugs
7 September 2020 Criminal court proceedings have been initiated in response to alleged breaches of the Therapeutic Goods Act 1989 by Brisbane-based company HEALTHHUB247 PTY LTD and its director.
TGA initiates court proceedings against Oxymed Australia and director Malcolm Hooper for alleged unlawful advertising
3 September 2020 TGA initiates court proceedings for alleged unlawful advertising of hyperbaric oxygen therapy chambers.
Federal Court restrains MMS Australia from advertising and supplying MMS and DMSO
4 June 2020 The Federal Court of Australia has made orders restraining MMS Australia from advertising and supplying goods containing certain potentially dangerous substances, including the main chemical used to make 'Miracle Mineral Solution' (MMS), until a further hearing next week.
TGA initiates court proceedings against MMS Australia and director Charles Barton for alleged unlawful advertising
29 May 2020 The TGA has initiated proceedings in the Federal Court of Australia in response to the alleged unlawful advertising of Miracle Mineral Supplement (MMS), dimethyl sulfoxide (DMSO) and other medicines by Southern Cross Directories Pty Ltd trading as MMS Australia.
Federal Court of Australia grants interim injunction to prevent advertising by Evolution Supplements Australia
16 April 2020 The Federal Court of Australia (Federal Court) has granted an interim injunction to prevent Evolution Supplements Australia Pty Ltd (Evolution Supplements Australia) and its sole director, Mr Cumhur Keskin, from advertising specified therapeutic goods.
Court proceedings commenced against Evolution Supplements Australia and its sole director for alleged advertising breaches
13 March 2020 The Secretary of the Department of Health has commenced proceedings in the Federal Court of Australia against Evolution Supplements Australia Pty Ltd (trading as Evolution Supplements Australia) and Mr Cumhur Keskin, the sole director and secretary of the company, for alleged breaches of the Therapeutic Goods Act 1989
$10 million penalty ordered against Peptide Clinics Pty Ltd for advertising breaches
23 July 2019 The Federal Court ordered that Peptide Clinics Australia (Peptide Clinics Pty Ltd) pay $10 million to the Commonwealth for breaches of the mandatory rules for advertising of medicines, including the ban on advertising prescription-only medicines to the public
TGA continues action against Peptide Clinics Australia for alleged advertising breaches
17 May 2019 The Federal Court has granted leave to the Secretary of the Department of Health to continue court proceedings against Peptide Clinics Australia following the company's liquidation in March this year.
TGA action against Peptide Clinics Pty Ltd for alleged advertising breaches
14 December 2018 This legal action follows an investigation by the Therapeutic Goods Administration
Reminder: supply and advertising controls on medicinal cannabis
3 May 2021 The TGA is reminding businesses involved with medicinal cannabis products of their regulatory obligations under the Therapeutic Goods Act 1989.
TGA to review advertising of stem cell therapies to the Australian public
7 April 2021 The TGA is investigating the advertising of stem cell therapies to ensure that content in the public domain complies with the Australian rules for advertising therapeutic goods.
Advertising of first aid creams containing bufexamac to cease in Australia
16 Sep 2020 Reminder to advertisers that first aid creams containing bufexamac cannot be advertised to Australian consumers from 18 September 2020.
Warning to consumers and advertisers about COVID-19 test kits
1 Apr 2020 COVID-19 tests must be done under the direction of a health professional. The advertising and sale of home tests is prohibited.
TGA issues warning about illegal advertising relating to COVID-19
24 Mar 2020 The TGA will take action in relation to the illegal advertising of therapeutic goods, including those that make false and misleading claims about preventing or curing COVID-19
Warning about products claiming to treat or prevent the novel coronavirus
7 Feb 2020 Certain therapeutic goods are being inappropriately promoted for the prevention or treatment of novel coronavirus (2019-nCoV) infections in Australia
Human placenta ingestion
19 Jan 2018 We are advising expectant mothers to be aware of the potential risks associated with placenta consumption